The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following Merck and Pfizer into what’s become a competitive development race.
The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following Merck and Pfizer into what’s become a competitive development race.
